Show simple item record

dc.contributor.authorFenning, Andrewen_US
dc.contributor.authorHarrison, Glennen_US
dc.contributor.authorRose'Meyer, Roselynen_US
dc.contributor.authorHoey, Andrewen_US
dc.contributor.authorBrown, Lindsayen_US
dc.date.accessioned2017-05-03T11:37:02Z
dc.date.available2017-05-03T11:37:02Z
dc.date.issued2005en_US
dc.identifier.issn03636135en_US
dc.identifier.doi10.1152/ajpheart.00140.2005en_US
dc.identifier.urihttp://hdl.handle.net/10072/4820
dc.description.abstractNitric oxide (NO) is essential for the normal functioning of the cardiovascular system. This study has determined whether chronic administration of L-arginine, the biological precursor of NO, attenuates the development of structural and functional changes in the hearts and blood vessels of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Uninephrectomised rats treated with DOCA, 25mg every 4th day sc, and 1% NaCl in the drinking water for 4 weeks developed hypertension, left ventricular hypertrophy with an increased left ventricular wall thickness and decreased ventricular internal diameter, increased ventricular interstitial and perivascular collagen deposition, increased passive diastolic stiffness, prolonged action potential duration and an inability to increase purine efflux in response to an increased workload. Administration of L-arginine (5% in food; 3.4?0.3 g/kg/day body weight) markedly attenuated or prevented these changes. Noradrenaline and acetylcholine produced decreased maximal responses in isolated thoracic aortic rings of DOCA-salt rats; L-arginine normalised these responses. Thus, L-arginine treatment prevents the development of hypertension and an increased cardiac stiffness following DOCA-salt treatment and attenuates ventricular and vascular remodelling, action potential prolongation and increased purine efflux. This study suggests that a functional NO deficit in blood vessels and the heart due to decreased NO synthase activity or increased release of reactive oxygen species such as superoxide may be a key change initiating many aspects of the cardiovascular impairment observed in DOCA-salt hypertensive rats. These changes can be prevented or attenuated by administration of L-arginine.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherAmerican Physiological Societyen_US
dc.publisher.placeUSAen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom1408en_US
dc.relation.ispartofpageto1416en_US
dc.relation.ispartofjournalAmerican Journal of Physiology - Heart and Circulatory Physiologyen_US
dc.relation.ispartofvolume289en_US
dc.rights.retentionNen_US
dc.subject.fieldofresearchcode320603en_US
dc.titleL-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats.en_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightSelf-archiving of the author-manuscript version is not yet supported by this journal. Please refer to the journal link for access to the definitive, published version or contact the author[s] for more information.en_US
gro.date.issued2015-02-04T04:26:36Z
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record